InSite Vision awarded broad US patent for bromfenac formulations, with protection through August 2029
M2 - Thu Jul 17, 8:29AM CDT
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite(R)
Business Wire - Wed Jul 16, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite's bromfenac product candidates, including BromSite(TM) (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite's pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex(TM) (ISV-504). Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.
InSite Vision to Webcast Annual Meeting of Stockholders on July 16, 2014
Business Wire - Tue Jul 15, 3:44PM CDT
InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, July 16, 2014 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a live webcast of the meeting, including a corporate presentation, available on the Investor Relations page of the company's website (www.insitevision.com). For those who miss the live broadcast, an archived replay will be available shortly thereafter.
InSite Vision to submit DexaSite's NDA to US FDA for blepharitis in adults in 2015
M2 - Wed Jul 09, 5:48AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) disclosed on Tuesday that it plans to submit a New Drug Application (NDA) for DexaSite (dexamethasone 0.1% in DuraSite) for the treatment of blepharitis in adults in 2015, following completion of remaining chemistry and manufacturing work and the meeting with the US Food and Drug Administration (FDA).
InSite Vision Plans to Submit New Drug Application to FDA for DexaSite(TM) for the Treatment of Blepharitis in Adults
Business Wire - Tue Jul 08, 7:30AM CDT
--European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 2014
InSite Vision Announces Agreement With Noteholders to Extinguish Debt in Exchange for One-Time Payment
Business Wire - Thu Jun 12, 7:30AM CDT
--InSite Will Now Directly Receive Tiered Royalties from Sales of AzaSite; Secured 16% Notes and Accrued Interest Liabilities Totaling $43.9 Cancelled
InSite Vision partners with Senju Pharmaceutical to develop and commercialise Azithromycin Ophthalmic Solution in Japan
M2 - Wed Jun 11, 7:07AM CDT
Ophthalmic products company Senju Pharmaceutical Co revealed on Tuesday the launch of a collaboration and license agreement to develop and market InSite Vision's (Other OTC:INSV) azithromycin ophthalmic solution using DuraSite including AzaSite 1% and AzaSite Xtra 2% ocular antibiotics in Japan.
InSite Vision and Senju Pharmaceutical Announce Collaboration to Develop and Commercialize Azithromycin Ophthalmic Solution Using DuraSite(R) in Japan
Business Wire - Tue Jun 10, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite(R) including AzaSite(R) 1% and AzaSite Xtra(TM) 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.
InSite Vision awarded USPTO's Notice of Allowance for Bromfenac formulations in DuraSite, BromSite, ISV-101 & BromDex
M2 - Thu Jun 05, 7:05AM CDT
Ophthalmologic products company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of a Notice of Allowance from the US Patent and Trademark Office (USPTO) for Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite.
InSite Vision Receives Notice of Allowance from USPTO Covering Bromfenac Formulations in DuraSite(R)
Business Wire - Wed Jun 04, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent claims contain both composition and method of treatment claims that will broadly cover all of InSite's bromfenac product candidates, including BromSite(TM) ((bromfenac 0.075%) ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite's pipeline that will be covered under this patent include: ISV-101 (bromfenac (0.01% to 0.04%) ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as bromfenac and dexamethasone containing products such as BromDex (ISV-504). The patent is expected to provide protection for bromfenac formulations in DuraSite to 2029.
Blepharitis Therapeutics Pipeline Review 2014
M2 - Fri May 30, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlrmcb/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Blepharitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Blepharitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - InSite Vision Incorporated - Foamix Ltd. - Laboratoires Thea S.A. - Kala Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/zl...lepharitis
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2014: 35 Companies Profiled
M2 - Thu May 29, 8:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9vcgd/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Alcon - Allergan - Bayer - Celsus Therapeutics - Circadian Technologies Limited - Digna Biotech - Dompe Farmaceutici - Dong-A Socio Holdings - Eleven Biotherapeutics - EyeGate Pharmaceuticals - HanAll Biopharma - InSite Vision Incorporated - Kainos Medicine - Kala Pharmaceuticals - Kissei Pharmaceutical - Laboratorios Sophia S.A. de C.V. - Laurantis Pharma Oy - Lipicard Technologies - Merck & Co. - Mimetogen Pharmaceuticals - Neuroptis Biotech - NovaBay Pharmaceuticals - Novaliq GmbH - Parion Sciences - PharmaNova - R-Tech Ueno - RegeneRx Biopharmaceuticals - Resolvyx Pharmaceuticals - Rigel Pharmaceuticals - SIFI For more information visit http://www.researchandmarkets.com/research/g9...njunctivit
InSite Vision Announces Positive Meeting With Swedish Medical Products Agency Regarding Filing for Marketing Approval of BromSite(TM)
Business Wire - Thu May 29, 7:31AM CDT
InSite Vision Incorporated (OTCBB: INSV) today announced that the Swedish Medical Products Agency (MPA) concluded that the existing Phase 3 clinical data for BromSite(TM) for the prevention of pain and inflammation in ocular surgery was likely sufficient to support the filing of a Marketing Authorization Application (MAA) with the MPA. Prior to the meeting with the MPA on May 26, 2014, InSite Vision had submitted substantial preliminary BromSite information to the Agency including CMC (chemistry, manufacturing, and controls) data, preclinical and clinical data sets and analytical methods.
Global Ocular Pain Therapeutics Pipeline Report 2014 - Insights into 5 Companies & 6 Drug Profiles
M2 - Tue May 27, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2lt264/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.disease. Companies Involved in Therapeutics Development - Sylentis S.A. - Bayer AG - InSite Vision Incorporated - Reata Pharmaceuticals, Inc. - Kala Pharmaceuticals, Inc. Drug Profiles - bromfenac sodium - mapracorat - SYL-1001 - loteprednol etabonate - RTA-408 - ketorolac tromethamine For more information visit http://www.researchandmarkets.com/research/2l...cular_pain
Global Ocular Inflammation Therapeutics Pipeline Review 2014 - Analysis of 17 Companies & 22 Drug Profiles
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j8lwqs/ocular) has announced the addition of the "Ocular Inflammation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Inflammation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - UMeWorld Limited - Sun Pharmaceutical Industries Limited - Bayer AG - InSite Vision Incorporated - Reata Pharmaceuticals, Inc. - Xigen SA - Enceladus Pharmaceuticals BV - SIFI S.p.A - Celsus Therapeutics Plc - Auven Therapeutics Management L.L.L.P - Cancer Therapeutics CRC Pty Ltd - Kala Pharmaceuticals, Inc. - Icon Bioscience, Inc. - Ocular Therapeutix, Inc. - Panmira Pharmaceuticals, LLC. - Clearside BioMedical, Inc. - Neuroptis Biotech Drug Profiles - bromfenac sodium - dexamethasone acetate - dexamethasone - mapracorat - dexamethasone acetate SR - XG-102 - RX-10045 - loteprednol etabonate - RTA-408 - triamcinolone acetonide - ketorolac tromethamine - AM-679 - SF-110 - SF-111 - OPX-1 - ARX-8203 - NOP-5 - Sun-0597 - LIMK1 AND LIMK2 Inhibitors - SF-101 - Liposomal corticosteroid - prednisolone For more information visit http://www.researchandmarkets.com/research/j8lwqs/ocular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
InSite Vision Reports First Quarter 2014 Financial Results
Business Wire - Wed May 14, 3:02PM CDT
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended March 31, 2014. Revenues for the quarter ended March 31, 2014 were $1.2 million compared to $5.3 million for the same period in 2013. Net loss for the quarter ended March 31, 2014 was $4.7 million, or $0.04 per share, compared to a net loss of $1.9 million, or $0.01 per share, in 2013. As of March 31, 2014, cash, cash equivalents and short-term investments totaled $5.4 million.
InSite Vision Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 27, 12:00PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter and year ended December 31, 2013. Revenues for the year ended December 31, 2013 were $30.8 million compared to $21.6 million for the same period in 2012. Net income for the year ended December 31, 2013 was $5.8 million, or $0.04 per share, compared to a net loss of $8.3 million, or $0.06 per share, in 2012. Revenues for the fourth quarter of 2013 were $1.1 million compared to $5.4 million for the same period in 2012. Net loss for the fourth quarter of 2013 was $5.0 million, or $0.04 per share, compared to a net loss of $1.8 million, or $0.01 per share, in the fourth quarter 2012. As of December 31, 2013, cash, cash equivalents and short-term investments totaled $8.3 million.
InSite Vision to Report Fourth Quarter and Year-End 2013 Financial Results on March 27, 2014
Business Wire - Fri Mar 21, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the fourth quarter and year-ended December 31, 2013 on Thursday, March 27, 2014.
InSite Vision receives USD1m in royalties from the sale of Besivance
M2 - Wed Feb 05, 4:47AM CST
US-based ophthalmologic company InSite Vision Incorporated (Other OTC:INSV) stated on Tuesday that Besivance 2013 net sales has generated an additional USD1m milestone payment.
InSite Vision Announces Achievement of the $1 Million Milestone From the Sale of Besivance(R) Royalty
Business Wire - Tue Feb 04, 7:30AM CST
InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.